

NOVARTIS AG  
Form 6-K  
October 11, 2002

[QuickLinks](#) -- Click here to rapidly navigate through this document

---

---

**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**PURSUANT TO RULE 13a-16 or 15d-16 OF  
THE SECURITIES EXCHANGE ACT OF 1934**

**Report on Form 6-K for date October 11, 2002**

**Novartis AG**

(Name of Registrant)

Lichtstrasse 35  
4056 Basel  
Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  Form 40-F

Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes  No

---

---

---

**Investor Relations**

**Novartis International AG**

CH-4002 Basel  
Switzerland  
Karen J Huebscher, PH.D.  
Tel +41 61 324 8433  
Nafida Bendali  
Tel +41 61 324 3514  
Sabine Moravi, MBA  
Tel + 41 61 324 8989  
Silke Zenter  
Tel +41 61 324 8612  
Francisco Bouzas  
Tel +41 61 324 8444  
Fax + 41 61 324 8844  
Internet Address:  
<http://www.novartis.com>

**INVITATION FOR MEETING, WEBCAST & TELEPHONE CONFERENCE**

**R&D Day and Q3 2002 Results Review**

Dear Investor

We are pleased to invite you to attend the Novartis R&D Day and review of Q3 2002. You may participate in person, via webcast or by teleconference. Please see the preliminary program on page 2.

Date: October 17, 2002

Time: 09.00 a.m. New York  
02.00 p.m. UK  
03.00 p.m. Switzerland

If attending in person: registration and coffee begin at 8:30 a.m  
Webcast or dial-in: test connection 10 minutes before program start

Location The Waldorf Astoria Hotel  
301 Park Avenue Grand Ballroom (3<sup>rd</sup> Floor; Lexington Ave entrance)  
New York, NY 10022

Phone numbers: Switzerland: +41 91 610 4111

United Kingdom: +44 (0) 207-866-4111

Europe Free-phone +800 2467 8700

US: +1 800 860 2442

Canada: 866-519-5086

You may also access the conference call as a live webcast on the Internet at: <http://www.novartis.com/investors> (under Upcoming Event). This information will be available for tests and for the submission of questions in advance from October 15, 2002.

***Preliminary Agenda***

***All times Eastern Standard/New York***

9:00 AM Introduction and Q3 Results

9:15 AM Review of recent product launches

---

10:35 AM Q&A (in person or via webcast only)

11:00 AM Break

11:30 AM Development/Functional Genomics/Conclusion

1:30 PM Presentations conclude

**Poster / booth session & luncheon**

2:30 PM Therapeutic area breakout sessions (Oncology, Transplant)

Edgar Filing: NOVARTIS AG - Form 6-K

[Programs will be taped and posted to the internet site October 18, 2002.]

3:30 PM End of R&D Day

Program presenters will include Daniel Vasella and others from senior management of Novartis.

\*\*\*\*\*

*Internet playback of presentations and therapeutic area breakout sessions may be viewed from the following times at www.novartis.com*

Date: **Friday, October 18, 2002**

Time: 2:00 p.m. Switzerland  
1:00 p.m. UK  
8:00 a.m. New York

**If you have not responded yet to attend the presentations in person  
and would like to do so, the reply form is attached for your use.**

Novartis  
Pharmaceutical Research & Development Day

Thursday, October 17  
The Waldorf Astoria Hotel Grand Ballroom  
New York, NY

**Reply Form**

- I will attend the New York Presentation
- I will follow the presentations on the Internet (a test link will be sent to you prior to the R&D Day)

First Name \_\_\_\_\_

Name \_\_\_\_\_

Company \_\_\_\_\_

Job Title \_\_\_\_\_

Country \_\_\_\_\_

Phone \_\_\_\_\_

Fax \_\_\_\_\_

E-mail \_\_\_\_\_

**To confirm your attendance, please e-mail or fax this form to Novartis Investor Relations by October 10, 2002.**

E-mail: [gabriella.gruber@group.novartis.com](mailto:gabriella.gruber@group.novartis.com)

Fax: +41 61 324 84 44, Attention: Gabriella Gruber

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**Novartis AG**

Date: October 11, 2002

By: /s/ MALCOLM B. CHEETHAM

Name: Malcolm B. Cheetham

Title: Head Group Financial Reporting and Accounting

---

QuickLinks

[INVITATION FOR MEETING, WEBCAST & TELEPHONE CONFERENCE](#)

[R&D Day and Q3 2002 Results Review](#)

[If you have not responded yet to attend the presentations in person and would like to do so, the reply form is attached for your use.](#)

[Reply Form](#)

[SIGNATURES](#)